18. September 2009 02:12
Hyperion Therapeutics, Inc. today announced that its investigational product HPN-100 (glycerol phenylbutyrate) has received orphan product designation from the U.S. Food and Drug Administration for intermittent or chronic treatment of patients with cirrhosis and any grade of hepatic encephalopathy.
The Company is planning to initiate a phase II clinical program in this indication later this year.
http://www.hyperiontx.com/
060b562e-0fad-4c15-bd91-8a2a46a14e98|0|.0
Posted in: Pharmaceutical News
Tags: Amenorrhea, Body Odor, Brain, Cirrhosis, Congestive Heart Failure, Edema, Gastroenterology, Haloperidol, Heart Failure, Hepatology, Hypersensitivity, Prescription Drug, Rare Disease, Valproic Acid
News-Medical.Net provides this medical information service in accordance
with these
terms and conditions.
Please note that medical information found
on this website is designed to support, not to replace the relationship
between patient and physician/doctor and the medical advice they may provide.